Jim Adox
Managing Director @ Venture Investors
Jim Adox is a Series B investor at Venture Investors focused on Health Care and Medical Device. Jim joined Venture Investors in 2007 as a Managing Director and heads up our Ann Arbor, Michigan office. He leverages his technical, operational and venture capital background by focusing on investment prospects in medical devices, hardware, software and communications.Jim’s prior venture capital experience includes a combined nine years as apartner at RidgeLine Ventures and EDF Ventures, where he led the spin-out, sourcing, financing, syndication and exit of numerous investments. During this time, he performed the role of President, CFO and COO of select opportunities until a management team was recruited. Jim served on the Boards of Directors of Avail Networks and HandyLab, and as an observer for Alfalight, Ardesta, TherOx and Xtera Communications.Prior to his venture capital positions, Jim had nine years operating experience both domestically and internationally. In these roles, he wore many functional hats: marketing, engineering, business development and operations.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Jim Adox invests in
Stages Jim Adox invests in
Countries Jim Adox invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 6 (30%)
- Medical Device 5 (25%)
- Medical 4 (20%)
- Biotechnology 3 (15%)
- iOS 1 (5%)
Stage
- Series B 6 (30%)
- Series A 5 (25%)
- Series C 3 (15%)
- Series D 1 (5%)
- Post-IPO Equity 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M / Series D / Aug 15, 2024 | |
EarliTec Diagnostics
|
EarliTec Diagnostics is a digital health company making earlier identification and treatment for ASD and related disabilities accessible to children everywhere. Developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, EarliTec is pioneering development of biomarkers that helpparents, providers and caregivers understand how a child is viewing the world. | $21.5M / Series B / Apr 02, 2024 | |
ViaLase
|
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. The company's system focuses on the development of micron-resolution OCT image-guided femtosecond laser technology to create micron-sized customized drainage channels through the trabecular meshwork that connects the anterior chamber to theSchlemm's canal without surgically opening or penetrating the eye, enabling medical professionals to improve glaucoma management with its efficient non-invasive treatment.ViaLase was incorporated in 2019 and is headquartered in Corona Del Mar, California. | $40M / Series C / Apr 01, 2024 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $85M / Convertible Note / Dec 13, 2022 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $40M / Series C / Jun 08, 2020 | |
SkySpecs
|
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.SkySpecs wasfounded on 2012 and is based in Ann Arbor, Michigan. | $17M / Series C / Dec 21, 2019 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $54.7M / Series C / Apr 08, 2019 | |
|
SkySpecs
|
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.SkySpecs wasfounded on 2012 and is based in Ann Arbor, Michigan. | $8.8M / Series B / Jan 09, 2018 | |
|
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $8.3M / Series B / Mar 13, 2017 | |
|
SkySpecs
|
SkySpecs automates the inspection, diagnostics, and maintenance of utility scale wind turbines with custom autonomous drones. The company develops an affordable form of energy, through the use of an automated drone inspection service and analytics platform that allows for repeatability, high-quality data, and safer inspections.SkySpecs wasfounded on 2012 and is based in Ann Arbor, Michigan. | $3M / Series A / Nov 09, 2015 | |
| See all 20 investments → | |||
Co-Investors
About Venture Investors
Turning innovation into health. Venture Investors seeks the next big things in healthcare. Based in the Midwest with open access to renowned research universities, and the vibrant communities that surround them, we target, uncover, and invest in extraordinary ideas that will shape the future of health and wellness. With decades of proven success,we’re fueling the future of what’s driving healthcare. Today, we have over $200 million in assets under management.
Venture Investors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Becky Hoerman
Controller
|
|||
David Arnstein
Chief Financial Officer and Managing Director
|
|||
Jake Simon
Principal Venture Partner
|
|||
|
Jim Adox
Managing Director
|
|||
John Neis
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jim Adox invest in?
Jim Adox invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jim Adox?
Public channels for Jim Adox include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jim Adox last invest?
The most recent investment recorded for Jim Adox closed in Aug 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
